Ответы
Ответы специалистов отмечены меткой «Специалист», их имена ведут на профиль.
Остерегайтесь мошенников, не высылайте никому деньги!
Ответы специалистов отмечены меткой «Специалист», их имена ведут на профиль.
Остерегайтесь мошенников, не высылайте никому деньги!
странная схема для таких инфекций. "метрид, цефтриаксон, вильпрафен, хилак, линекс, микосист, витапрост".
видимо доктор не совсем компетентен. либо вы недопонимаете свою проблему.
вы с головой не дружите.
вам не писали
выпили азитрокс.
зайтите в любой КВД
после
http://mosderm.ru/kontakty/adresa-filialov
будет чистый анализ
если хдамидиоз не осложненный
Chlamydial Infections in Adolescents and Adults
Chlamydial genital infection is the most frequently reported infectious disease in the United States, and prevalence is highest in persons aged ≤25 years (93). Several important sequelae can result from C. trachomatis infection in women, the most serious of which include PID, ectopic pregnancy, and infertility. Some women who have uncomplicated cervical infection already have subclinical upper-reproductive–tract infection upon diagnosis.
Asymptomatic infection is common among both men and women. To detect chlamydial infections, health-care providers frequently rely on screening tests. Annual screening of all sexually active women aged ≤25 years is recommended, as is screening of older women with risk factors (e.g., those who have a new sex partner or multiple sex partners). In June 2007, USPSTF reviewed and updated their chlamydia screening guidance and found that the epidemiology of chlamydial infection in the United States had not changed since the last review (81,271). In issuing recommendations, USPSTF made the decision to alter the age groups used to demonstrate disease incidence (i.e., from persons aged ≤25 years to those aged ≤24 years). CDC has not changed its age cutoff, and thus continues to recommend annual chlamydia screening of sexually active women aged ≤25 years.
Screening programs have been demonstrated to reduce both the prevalence of C. trachomatis infection and rates of PID in women (272,273). Although evidence is insufficient to recommend routine screening for C. trachomatis in sexually active young men because of several factors (including feasibility, efficacy, and cost-effectiveness) (94), the screening of sexually active young men should be considered in clinical settings with a high prevalence of chlamydia (e.g., adolescent clinics, correctional facilities, and STD clinics). Among women, the primary focus of chlamydia screening efforts should be to detect chlamydia and prevent complications, whereas targeted chlamydia screening in men should only be considered when resources permit and do not hinder chlamydia screening efforts in women (274,275). An appropriate sexual risk assessment should be conducted for all persons and might indicate more frequent screening for some women or certain men (see MSM).
Diagnostic Considerations
C. trachomatis urogenital infection in women can be diagnosed by testing urine or by collecting swab specimens from the endocervix or vagina. Diagnosis of C. trachomatis urethral infection in men can be made by testing a urethral swab or urine specimen. Rectal C. trachomatis infections in persons that engage in receptive anal intercourse can be diagnosed by testing a rectal swab specimen. NAATs, cell culture, direct immunofluorescence, EIA, and nucleic acid hybridization tests are available for the detection of C. trachomatis on endocervical specimens and urethral swab specimens from men (197). NAATs are the most sensitive tests for these specimens and are FDA-cleared for use with urine. Some NAATs are cleared for use with vaginal swab specimens, which can be collected by a provider or self-collected by a patient. Self-collected vaginal swab specimens perform at least as well as with other approved specimens using NAATs (276,277), and women find this screening strategy highly acceptable. Rectal and oropharyngeal C. trachomatis infection in persons engaging in receptive anal or oral intercourse can be diagnosed by testing at the anatomic site of exposure. Most tests, including NAAT and nucleic acid hybridization tests, are not FDA-cleared for use with rectal or oropharyngeal swab specimens, and chlamydia culture is not widely available for this purpose. However, NAATs have demonstrated improved sensitivity and specificity compared with culture for the detection of C. trachomatis at rectal sites (278-280) and at oropharyngeal sites among men (278-281). Some laboratories have met CLIA requirements and have validated NAAT testing on rectal swab specimens for C. trachomatis. Recent evidence suggests that the liquid-based cytology specimens collected for Pap smears might be acceptable specimens for NAAT testing, although test sensitivity using these specimens might be lower than those resulting from the use of cervical swab specimens (282); regardless, certain NAATs have been FDA-cleared for use on liquid-based cytology specimens. Persons who undergo testing and are diagnosed with chlamydia should be tested for other STDs.
Treatment
Treating infected patients prevents sexual transmission of the disease, and treating all sex partners of those testing positive for chlamydia can prevent reinfection of the index patient and infection of other partners. Treating pregnant women usually prevents transmission of C. trachomatis to infants during birth. Chlamydia treatment should be provided promptly for all persons testing positive for infection; delays in receiving chlamydia treatment have been associated with complications (e.g., PID) in a limited proportion of chlamydia-infected subjects (283). Coinfection with C. trachomatis frequently occurs among patients who have gonococcal infection; therefore, presumptive treatment of such patients for chlamydia is appropriate (see Gonococcal Infection, Dual Therapy for Gonococcal and Chlamydial Infections). The following recommended treatment regimens and alternative regimens cure infection and usually relieve symptoms.
Recommended Regimens
Azithromycin (ЭТО АЗИТРОКС) 1 g orally in a single dose
OR
Doxycycline 100 mg (ЭТО СОЛЮТАБ ЮНИКОС) orally twice a day for 7 days
http://www.cdc.gov/std/treatment/2010/chlamydial-infections.htm
все другое выброс денег
Кобелякин совсем уже ленится, не может нормально ответить
я задавал вопрос, его видимо удалили, - если я приму азитрокс , будут ли конфликты с другими антибиотиками указанные выше?
и еще по поводу дозировки 1 таблетка и все, а в упаковки 3 таблетки?
НУ НАПИСАЛ ЖЕ.
ничЕго другого принимать не нужно!
из вышеперечисленных вами названий только одно антибиотик, но его не нужно.
есть классика - азитромицин, азитрокс.
https://health.mail.ru/drug/azithrox/
2 капусулы сегодня
2 завтра
и всё
потом через неделю в КВД на повторный соскоб, ПЦР
если вы еще потянете неделю, то у вас будет осложненный хламидиоз.
поторопитесь с 4 таблетками азитрокса за 2 дня.